/
PPBT
$1.80+$0.06 (+3.45%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.6M
1M shares
52-week range
$1.42 – $29.00
1% from low
Exchange
NASDAQ
ADRC
Borrow rate
53.39%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-972.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.0M | $1.0M | $0 | $0 | $195.8K | $0 | $0 |
| Cost of revenue | $0 | $80 | $58 | $55 | $120 | $196.0K | $186.0K | $0 |
| Gross profit | $1.0M | $999.9K | $999.9K | −$55 | −$120 | −$196 | −$186.0K | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | -0.1% | — | — |
| R&D | $5.3M | $2.3M | $7.5M | $11.8M | $16.3M | $17.0M | $7.6M | $3.7M |
| Operating income | −$7.8M | −$7.2M | −$13.2M | −$17.9M | −$22.6M | −$22.3M | −$11.0M | −$27.5M |
| EBITDA | −$5.6M | −$6.1M | −$28.4M | −$17.5M | −$21.5M | −$19.9M | −$7.1M | −$26.3M |
| Net income | −$5.2M | −$5.8M | −$28.0M | −$18.4M | −$21.7M | −$19.9K | −$7.2M | −$26.4M |
| Net margin | -520.0% | -585.0% | -2799.9% | — | — | -10.2% | — | — |
| EPS (diluted) | -740.00 | -560.00 | -500.00 | -200.00 | -240.00 | -180.00 | -44.20 | -11080.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-5.31 | $-5.31–$-5.31 | 1 |
| 2027 | $36M | $-0.88 | $-0.88–$-0.88 | 1 |
| 2028 | $7M | $-0.15 | $-0.15–$-0.15 | 1 |
| 2029 | $33M | $0.07 | $0.07–$0.07 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2821.86
Price
$1.80
Implied upside
+156670%
Peer comparison
Purple Biotech Ltd. American Depositary Shares
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
www.purple-biotech.com- Employees
- 10
- IPO / List date
- Nov 20, 2015
Held by traders on TradeandTell
No one on the platform currently holds PPBT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PPBT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-02 | 1-for-10reverse |
| 2024-09-17 | 1-for-20reverse |
| 2020-08-21 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded PPBT yet.
